Cannabis trial for endometriosis pain failed because participants could not stop driving

A three-armed RCT comparing inhaled THC + CBD oil, CBD oil alone, and placebo for endometriosis pain recruited only 12 of 63 intended participants, with most dropping out due to driving restrictions.

Chesterman, Susan et al.·Complementary therapies in clinical practice·2025·Preliminary EvidenceRandomized Controlled Trial
RTHC-06208Randomized Controlled TrialPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Preliminary Evidence
Sample
N=63

What This Study Found

Only 12 of 63 target participants enrolled; 7 withdrew and only 4 completed; the primary barrier was the requirement to abstain from driving during THC treatment; high withdrawal rate made efficacy assessment impossible.

Key Numbers

12 of 63 target enrolled; 7 withdrew; 4 completed; 1 lost to follow-up; 10 adverse events (8 possibly cannabis-related); 2 serious adverse events (unrelated).

How They Did This

Three-armed RCT in Australia comparing inhaled THC (16%) flower + CBD oil (100mg/mL), CBD oil alone, or placebo oil; aimed for 63 participants; assessed safety, acceptability, and feasibility.

Why This Research Matters

Despite strong patient interest in cannabis for endometriosis, practical barriers like driving restrictions make clinical trials nearly impossible, leaving a major evidence gap.

The Bigger Picture

The tension between cannabis clinical research and real-world constraints represents a systemic barrier to generating the evidence base that patients and clinicians need.

What This Study Doesn't Tell Us

Failed to achieve recruitment target; cannot assess efficacy; Australian regulatory context; small enrolled sample prevents meaningful safety conclusions.

Questions This Raises

  • ?Can future trials use designs that accommodate driving needs?
  • ?Would evening-only dosing or CBD-only arms improve recruitment?
  • ?How can cannabis research overcome practical barriers?

Trust & Context

Key Stat:
Only 4 of 63 target participants completed the trial due to driving restrictions
Evidence Grade:
Feasibility RCT that failed its primary goal; valuable as a cautionary report for future trial design.
Study Age:
Published 2025
Original Title:
Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.
Published In:
Complementary therapies in clinical practice, 61, 102023 (2025)
Database ID:
RTHC-06208

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

Why did the trial fail?

The main barrier was the requirement to abstain from driving while using THC-containing cannabis. Most participants could not comply with this restriction in their daily lives.

Is there evidence cannabis helps endometriosis?

People with endometriosis commonly report using cannabis for symptoms, but this trial failure means controlled clinical evidence remains absent.

Read More on RethinkTHC

Cite This Study

RTHC-06208·https://rethinkthc.com/research/RTHC-06208

APA

Chesterman, Susan; Mikocka-Walus, Antonina; Sinclair, Justin; Druitt, Marilla; Furyk, Jeremy; Evans, Subhadra; Abbott, Jason; Eathorne, Alexandra; Martin, Alexander; Ng, Cecilia; Nguyen, Lisa; Oldfield, Karen; Romano, Daniel; Sarris, Jerome; Semprini, Alex; Stanley, Katherine; Armour, Mike. (2025). Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.. Complementary therapies in clinical practice, 61, 102023. https://doi.org/10.1016/j.ctcp.2025.102023

MLA

Chesterman, Susan, et al. "Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.." Complementary therapies in clinical practice, 2025. https://doi.org/10.1016/j.ctcp.2025.102023

RethinkTHC

RethinkTHC Research Database. "Challenges in conducting a feasibility randomized controlled..." RTHC-06208. Retrieved from https://rethinkthc.com/research/chesterman-2025-challenges-in-conducting-a

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.